Manmohan Singh

US Patent:

20130101609, Apr 25, 2013

Filed:

Jan 24, 2011

Appl. No.:

13/574958

Inventors:

Derek O'Hagan - Winchester MA, US
Manmohan Singh - Cary NC, US
Siddhartha Jain - Troy NY, US
Padma Malyala - Acton MA, US

Assignee:

NOVARTIS AG - Basel

International Classification:

A61K 9/14
A61J 1/00

US Classification:

4241841, 206438

Abstract:

In one aspect, the present invention provides sterile microparticle compositions comprising biodegradable microparticles, which comprise at least one biodegradable polymer. In other aspects, the present invention provides methods of making and using such compositions as well as articles of manufacture and kits containing the same.

US Patent:

20130183355, Jul 18, 2013

Filed:

Jun 7, 2011

Appl. No.:

13/808245

Inventors:

Siddhartha Jain - Troy NY, US
Derek O'Hagan - Winchester MA, US
Manmohan Singh - Cary NC, US

Assignee:

NOVARTIS AG - Basel

International Classification:

A61K 39/385

US Classification:

424400, 4241931, 42419611, 42419711

Abstract:

Particle compositions comprising adsorbed RNA replicons as well as methods of making and using the same are described.

US Patent:

20130195898, Aug 1, 2013

Filed:

Sep 15, 2012

Appl. No.:

13/621174

Inventors:

Derek O'Hagan - Winchester MA, US
Gary S. Ott - Oakland CA, US
John Donnelly - Moraga CA, US
Jina Kazzaz - San Rafael CA, US
Mildred Ugozzoli - San Rafael CA, US
Manmohan Singh - Cary NC, US
John Barackman - Dublin CA, US

Assignee:

Novartis Vaccines and Diagnostics, Inc. - Emeryville CA

International Classification:

A61K 39/39

US Classification:

4241841, 4242831

Abstract:

Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(α-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biologically active macromolecules, such as DNA, polypeptides, antigens, and adjuvants. Also provided are compositions of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. Immunogenic compositions having an immunostimulating amount of an antigenic substance, and an immunostimulating amount of an adjuvant composition are also provided. Methods of stimulating an immune response, methods of immunizing a host animal against a viral, bacterial, or parasitic infection, and methods of increasing a Th1 immune response in a host animal by administering to the animal an immunogenic composition of the microparticles, and/or microemulsions of the invention, are also provided.

US Patent:

20130195968, Aug 1, 2013

Filed:

Jul 6, 2011

Appl. No.:

13/808089

Inventors:

Andrew Geall - Littleton MA, US
Christian Mandl - Lexington MA, US
Derek O'Hagan - Winchester MA, US
Manmohan Singh - Cary NC, US

Assignee:

Novartis AG - Basel

International Classification:

A61K 9/50

US Classification:

424450, 424490, 4241841, 4242341, 4242041, 4242741, 4242651, 4242111

Abstract:

Nucleic acid immunisation is achieved by delivering a self-replicating RNA encapsulated within a small particle. The RNA encodes an immunogen of interest, and the particle may deliver this RNA by mimicking the delivery function of a natural RNA virus. Thus the invention provides a non-virion particle for in vivo delivery of RNA to a vertebrate cell, wherein the particle comprises a delivery material encapsulating a self-replicating RNA molecule which encodes an immunogen. These particles are useful as components in pharmaceutical compositions for immunising subjects against various diseases.

US Patent:

20130236492, Sep 12, 2013

Filed:

Mar 8, 2013

Appl. No.:

13/790948

Inventors:

- Basel, CH
Derek O'HAGAN - Winchester MA, US
Manmohan SINGH - Cary NC, US
Simone BUFALI - Siena, IT

Assignee:

NOVARTIS AG - Basel

International Classification:

A61K 39/39

US Classification:

4242011, 4242031

Abstract:

The invention improves TdaP vaccines by including a TLR agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response.

US Patent:

20130243841, Sep 19, 2013

Filed:

Jun 1, 2011

Appl. No.:

13/700437

Inventors:

Sushma Kommareddy - Waltham MA, US
Derek O'Hagan - Winchester MA, US
Manmohan Singh - Cary NC, US
Amanda Scampini Bonificio - Cambridge MA, US
Barbara Baudner - Siena, IT

Assignee:

Novartis AG - Basel

International Classification:

A61K 9/00

US Classification:

424422, 4241841, 4242341, 4242041, 4242741, 4242651, 4242091, 424443

Abstract:

A process for preparing a lyophilised vaccine antigen, comprising steps of (i) increasing the concentration of an antigen in a liquid composition including that antigen using centrifugal filtration and/or ultrafiltration, to provide a concentrated antigen, and (ii) lyophilising the concentrated antigen, to provide the lyophilised vaccine antigen. The lyophilised material can be reconstituted and used for vaccine formulation. The process is particularly useful with influenza vaccine antigens.

US Patent:

20130274465, Oct 17, 2013

Filed:

Sep 1, 2011

Appl. No.:

13/820370

Inventors:

Manmohan Singh - Cary NC, US
David A.G. Skibinski - Singapore, SG
Tom Yao-Hsiang Wu - San Diego CA, US
Yongkai Li - San Diego CA, US
Alex Cortez - San Diego CA, US
Xiaoyue Zhang - San Diego CA, US
Yefen Zou - San Diego CA, US
Timothy Z. Hoffman - San Diego CA, US
Jianfeng Pan - San Diego CA, US
Kathy Yue - Minneapolis MN, US

Assignee:

IRM LLC - Hamilton
NOVARTIS AG - Basel

International Classification:

C07F 9/6561
C07F 9/645
C07F 9/6558
C07F 9/6512

US Classification:

540542, 546 23, 544244, 544243

Abstract:

Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

US Patent:

20140017285, Jan 16, 2014

Filed:

Mar 23, 2012

Appl. No.:

14/005525

Inventors:

Luis Brito - Concord MA, US
Manmohan Singh - Cary NC, US
Derek O'Hagan - Winchester MA, US

Assignee:

NOVARTIS AG - BASEL

International Classification:

A61K 47/24
A61K 9/107

US Classification:

424400, 4242831, 4241841

Abstract:

To formulate amphiphilic pharmacological agents (in particular, amphiphilic immunopotentiators) in oil-in-water emulsions the invention provides an oil-in-water emulsion comprising an aqueous phase, an oil phase, a surfactant, and a phospholipid.